CRISPR Therapeutics AG

CRSPNASDAQ • USD
42.24 USD
↘ 0.38 (0.89%)AT CLOSE (03:59 PM EST)
42.33
↗ 0.09 (0.20%)
POST MARKET (AS OF 07:58 PM EST)
Post Market
AS OF 07:58 PM EST
42.33
↗ 0.09 (0.20%)
🔴Market: CLOSED

CRISPR Therapeutics AG (CRSP) is currently trading at $42.21. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. CRSP is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$42.50
High?$42.79
Low?$41.75
Prev. Close?$42.62
Volume?1.9M
Avg. Volume?1.7M
VWAP?$42.28
Rel. Volume?1.13x
Bid / Ask
Bid?$42.10 × 100
Ask?$42.55 × 400
Spread?$0.45
Midpoint?$42.33
Valuation & Ratios
Market Cap?4.1B
Shares Out?97.0M
Float?76.8M
Float %?79.5%
P/E Ratio?N/A
P/B Ratio?2.49
EPS?-$4.70
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Employees
393
Market Cap
4.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2016-10-19
Address
BAARERSTRASSE 14
ZUG,
Phone: (617) 315-4600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
29
Momentum?
90
Short Sent.?
39
Piotroski F-Score?1/9Weak
Altman Z-Score?1.79Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.37%Squeeze Risk
Short Interest?17.2M
Days to Cover?13.1
Free Float76.8M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?16.21Strong
Quick Ratio?16.21Strong
Cash Ratio?1.36Strong
Debt/Equity?0.36Low
ValuationFAIRLY VALUEDvs 8 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
56
S&P
64
2.49CHEAP▾
P/S?
Peers
13
S&P
3
162.77HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-8.7CHEAP▾
EV/Sales?
Peers
13
S&P
3
178.46HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
6
-27.7%WEAK▾
ROA?
Peers
50
S&P
3
-17.8%WEAK▾
Cash Flow & Enterprise
FCF?$-376715000
Enterprise Value?$4.5B
Fundamentals ratios updated end of day